Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling

This publication has 42 references indexed in Scilit:

• The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects
  Int. Journal of Clinical Pharmacology and Therapeutics, 2013
• Intestinal permeability and its relevance for absorption and elimination
  Xenobiotica, 2007
• Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method
  British Journal of Clinical Pharmacology, 2004
• Pharmacokinetics of Intravenous, Single‐Dose Tiotropium in Subjects with Different Degrees of Renal Impairment
  The Journal of Clinical Pharmacology, 2004
• The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers
  The Journal of Clinical Pharmacology, 2004
• Systemic availability and lung deposition of budesonide via three different nebulizers in adults
  Annals of Allergy, Asthma & Immunology, 2003
• Single‐Dose and Steady‐State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus® or Turbohaler® Dry‐Powder Inhalers to Healthy Subjects
  The Journal of Clinical Pharmacology, 2001
• PREDICTING REGIONAL LUNG DOSAGES OF A NEBULIZED SUSPENSION: PULMICORT® (BUDESONIDE)
  Particulate Science and Technology, 1997
• Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI
  European Respiratory Journal, 1994
• Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers.
  Thorax, 1991